Samsung Bioepis, developer of the biosimilar trastuzumab, Ontruzant, and Genentech, maker of the reference trastuzumab, Herceptin, have asked a court to dismiss their patent litigation.
Samsung Bioepis, developer of the biosimilar trastuzumab, Ontruzant, and Genentech, maker of the reference trastuzumab, Herceptin, have asked a court to dismiss their patent litigation.
Late last month, the 2 companies filed a joint stipulation of dismissal with the United States District Court for the District of Delaware for a Biologics Price Competition and Innovation Act (BPCIA) litigation. According to the stipulation, the companies have entered into a settlement agreement and are voluntarily dismissing all claims and counter claims asserted in the litigation.
The terms of the settlement were not disclosed by either company, and no date for a launch of the biosimilar trastuzumab in the United States has been announced.
The settlement is the fourth known agreement between the Herceptin maker and a biosimilar challenger. Fellow biosimilar maker Mylan, which developed Ogivri with its partner Biocon, also settled with Genentech over Herceptin patents and withdrew its pending inter partes review challenges in 2017.
Additionally, Celltrion and Teva, makers of Herzuma, reached a settlement with Genentech and agreed to dismiss their BPCIA litigation in late 2018.
Pfizer, maker of Trazimera, also settled with Genentech in late 2018.
Launch dates for these biosimilar trastuzumab options have not been publicly disclosed, either; however, Mylan, when it announced its settlement, said that it anticipated being the first company to launch a biosimilar trastuzumab product in the United States.
Meanwhile, 1 remaining developer with an approved biosimilar trastuzumab has not settled with the Herceptin maker: Amgen, which recently received approval for Kanjinti, is currently in a BPCIA dispute with Genentech, and Genentech has reportedly filed a motion for a temporary restraining order and a preliminary injunction against Amgen in the case.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.